Autologous Bone Marrow Transplantation - Blog Science Connections

Lymphoma: Purging and Detecting
K. Anderson and G. Phillips, Chairmen
DR. C. GORIN: Dr. Barlogie, did you try to purge marrow with J5 or with
any other anticommon acute lymphoblastic leukemic antigen monoclonal
antibody?
DR. B. BARLOGIE: NO, we didn't.
DR. A. GEE: 1 was interested in asking Bob Bast whether addition of a
second monoclonal antibody rather than a chemotherapeutic agent increased
the cell kill or whether your cells that were left behind were, for example, low
density and sensitive in that way.
DR. R. "BOB" BAST: The problem didn't seem to be killing the lymphoma
cells so much, at least with the immunotoxin, as it was killing the
normal marrow precursors. We could eliminate every last lymphoma cell that
we could measure, provided that you can go high enough on the dosage. It
may be with the second antibody that we might get additive effects against the
lymphoma and not additive effects against the CFCIs-GM. We have looked for
bystander effects with a B-lymphoma line, mixed with the T lymphoma and
the immunotoxin. And we don't see bystander killing. So, presumably, there
is something going on that is a bit more specific in terms of the marrow
toxicity.
371